The pridopidine paradox in Huntington's disease

Movement Disorders

Volumn 28, Issue 10, 2013, Pages 1321-1324

  Reilmann, Ralf ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PRIDOPIDINE; TETRABENAZINE;

CHOREA; DRUG MEGADOSE; DRUG SCREENING; EDITORIAL; HUMAN; HUNTINGTON CHOREA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNIFIED HUNTINGTON DISEASE RATING SCALE;

DOPAMINE AGENTS; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; PIPERIDINES;

EID: 84884720110     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25559     Document Type: Editorial

References (30)

1. The Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord 2013;28:1407-1415.
2. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
3. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol 2010;33:260-264.
4. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10:1049-1057.
5. Reilmann R, Roos RA, Rosser A, et al. A teaching film, video library and online certification for the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS) [Abstract]. Akt Neurol 2009;36(Suppl 2):116-117.
6. Reilmann R. Huntington's disease: towards disease modification-gaps and bridges, facts and opinions. Basal Ganglia 2012;2:241-248.
7. Feigin A. Pridopidine in treatment of Huntington's disease: beyond chorea? Lancet Neurol 2011;10:1036-1037.
8. Landwehrmeyer GB, Marder K, Biilmann-Ronn B, et al. Effects of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington's disease: a meta-analysis [Abstract]. Clin Genet 2011;80(Suppl 1):48.
9. Dyhring T, Nielsen EO, Sonesson C, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 2010;628:19-26.
10. Ponten H, Kullingsjo J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 2010;644:88-95.
11. Rung JP, Carlsson A, Markinhuhta KR, et al. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:833-839.
12. Tedroff J, Torstenson R, Hartvig P, et al. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse 1998;28:280-287.
13. Natesan S, Svensson KA, Reckless GE, et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 2006;318:810-818.
14. Kara E, Lin H, Svensson K, et al. Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 2010;161:1343-1350.
15. Seeman P, Tokita K, Matsumoto M, et al. The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors. Synapse 2009;63:930-934.
16. Venuto CS, McGarry A, Ma Q, et al. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012;27:31-41.
17. Tadori Y, Kitagawa H, Forbes RA, et al. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 2007;574:103-111.
18. Sahlholm K, Arhem P, Fuxe K, et al. The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor. Mol Psychiatry 2013;18:12-14.
19. Osterberg O, Ivkovic J, Sundgreen C, et al. A single center, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of multiple-ascending doses of pridopidine in healthy volunteers [Abstract]. Sixth Annual Huntington Disease Clinical Research Symposium. Neurotherapeutics 2012;9:1-17.
20. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
21. Bohlen S, Ekwall C, Hellström K, et al. Physical therapy in Huntington's disease-toward objective assessments? Eur J Neurol 2013;20:389-393.
22. Kloos AD, Kegelmeyer DA, Young GS, et al. Fall risk assessment using the Tinetti mobility test in individuals with Huntington's disease. Mov Disord 2010;25:2838-2844.
23. Busse ME, Wiles CM, Rosser AE. Mobility and falls in people with Huntington's disease. J Neurol Neurosurg Psychiatry 2009;80:88-90.
24. Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010;75:2150-2160.
25. Reilmann R, Bohlen S, Klopstock T, et al. Grasping premanifest Huntington's disease-shaping new endpoints for new trials. Mov Disord 2010;25:2858-2862.
26. Reilmann R, Kirsten F, Quinn L, et al. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology 2001;57:920-924.
27. Reilmann R, Rumpf S, Beckmann H, et al. Huntington's disease: objective assessment of posture-a link between motor and functional deficits. Mov Disord 2012;27:555-559.
28. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
29. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
30. Biglan KM. Tapping in Huntington disease: a path forward to preventive therapies? Neurology 2010;75:2142-2143.